Sugammadex

Clinical use: how to give it (practical structure)

• Confirm need for reversal and quantify block with objective monitoring (TOF/PTC); ensure airway/ventilation plan if reversal fails.
  • Prefer quantitative TOF ratio; aim TOF ≥ 0.9 before extubation.
• Dose by depth of block (ideal body weight often used in obesity; follow local policy/product info).
  • Moderate block (reappearance of T2): 2 mg/kg IV.
  • Deep block (PTC 1–2, no TOF twitches): 4 mg/kg IV.
  • Immediate reversal after rocuronium 1.2 mg/kg (cannot intubate/cannot ventilate scenario): 16 mg/kg IV.
• After administration: continue monitoring for recurarisation, ventilation adequacy, and haemodynamic stability; document TOF ratio and dose.
  • If inadequate reversal: consider under-dosing, wrong NMBA (benzylisoquinolinium), ongoing NMBA infusion, severe acidosis/hypothermia, or equipment/monitoring error.
• If further paralysis required after sugammadex: avoid rocuronium/vecuronium initially; consider non-steroidal NMBA (e.g. atracurium/cisatracurium) or high-dose rocuronium with awareness of delayed onset/need for large doses.
  • If re-paralysis needed soon after sugammadex, benzylisoquinoliniums are preferred; if rocuronium is used, may require larger dose and onset may be delayed due to binding.

Classification and mechanism

• Modified γ-cyclodextrin; a selective relaxant binding agent.
• Encapsulates aminosteroid NMBAs (highest affinity: rocuronium > vecuronium >> pancuronium) forming a tight water-soluble complex.
• Reduces free plasma NMBA concentration → creates gradient drawing NMBA away from neuromuscular junction → rapid recovery without relying on AChE inhibition.
• No muscarinic effects; no need for anticholinergic co-administration.

Indications

• Reversal of rocuronium– or vecuronium-induced neuromuscular block (including deep block).
• Rapid reversal when immediate recovery is required (e.g. failed airway after rocuronium).
• When neostigmine is contraindicated or undesirable (e.g. severe bradycardia risk, need for deep block reversal).

Dosing and onset (exam numbers)

• 2 mg/kg IV: moderate block (T2 present).
• 4 mg/kg IV: deep block (PTC 1–2).
• 16 mg/kg IV: immediate reversal after high-dose rocuronium (e.g. 1.2 mg/kg).
• Typical recovery times: faster than neostigmine; deep block reversal can occur within a few minutes when appropriately dosed (varies with depth, NMBA, and patient factors).

Pharmacokinetics

• Administration: IV bolus.
• Distribution: extracellular fluid; low protein binding.
• Metabolism: minimal; not significantly metabolised.
• Elimination: renal excretion of unchanged sugammadex and sugammadex–NMBA complex.
• Half-life: ~2 hours in normal renal function (prolonged in renal impairment).

Pharmacodynamics and monitoring

• Effect depends on molar equivalence: inadequate dose risks incomplete reversal and recurarisation.
• Use quantitative neuromuscular monitoring; clinical tests alone are unreliable.
• Does not reverse benzylisoquinolinium NMBAs (atracurium, cisatracurium, mivacurium).

Adverse effects and complications

• Anaphylaxis/hypersensitivity: rare but reported; treat as per anaphylaxis guidelines.
• Bradycardia (occasionally severe/asystole): monitor; treat with anticholinergic/epinephrine as clinically indicated.
• Recurarisation: usually due to under-dosing, very deep block, or ongoing rocuronium infusion; ensure correct dose and monitoring.
• Coagulation tests: transient increases in aPTT/PT reported in some studies; clinical bleeding signal generally low but consider in high-risk bleeding contexts.
• Nausea/vomiting, headache, injection site reactions: reported.
• Potential for displacement interactions: other drugs with cyclodextrin affinity may theoretically displace NMBA (clinically uncommon); more relevant is binding of some steroidal compounds by sugammadex.

Contraindications, cautions, and special populations

• Severe renal impairment (e.g. eGFR < 30 mL/min/1.73 m²): avoid or use only with strong justification due to prolonged retention of complex and limited safety data.
• Pregnancy/breastfeeding: limited data; use if benefits outweigh risks; note potential interaction with hormonal contraception.
• Paediatrics: used in many centres; dosing principles similar; follow local guidance/product licence.
• Obesity: dosing strategy varies (actual vs ideal/adjusted body weight); under-dosing risks failure; follow institutional policy and monitor quantitatively.
• Hepatic impairment: no major effect on elimination (renal), but may affect NMBA pharmacology; dose to monitoring.

Drug interactions (high-yield)

• Hormonal contraception: can reduce exposure to progestogen (acts like a missed pill). Advise additional non-hormonal contraception for 7 days after administration (typical product advice).
• Toremifene (and some other steroidal/structurally related drugs): potential to displace rocuronium/vecuronium from complex → risk of recurarisation (rare; be vigilant).
• If neostigmine has already been given: sugammadex can still work for aminosteroids, but ensure monitoring and consider bradycardia/PONV from AChE inhibitor already administered.

Comparison with neostigmine (core viva points)

• Mechanism: sugammadex encapsulates NMBA; neostigmine increases ACh at NMJ (AChE inhibition).
• Depth of block: sugammadex can reverse deep rocuronium/vecuronium block; neostigmine is unreliable/slow in deep block and has a ceiling effect.
• Side effects: sugammadex—hypersensitivity/bradycardia; neostigmine—bradycardia, bronchospasm, secretions, GI effects; requires antimuscarinic.
• Monitoring: both require objective monitoring; sugammadex failure usually dosing/agent related; neostigmine failure often due to deep block or inadequate time.